UNIVERSITY AT BUFFALO - JACOBS SCHOOL OF MEDICINE AND BIOMEDICAL SERVICES - March 1, 2022
"Lipshultz says the research validates that dexrazoxane is safe and effective for protecting the hearts of pediatric cancer patients from the toxicity of chemotherapeutic drugs even 18 years later. 'The goal for these survivors is to have them thrive as adults and live productive lives well beyond when they leave the hospital. This will hopefully offer survivors the hope and opportunity for a brighter future. Our survivorship research allows us now to ‘begin with the end in mind’ by using an effective cardioprotective treatment,' Lipshultz adds." Read Article>>
Comments